6-hydroxydopamine affects multiple pathways to induce cytotoxicity in differentiated LUHMES dopaminergic neurons.

6-hydroxydopamine Apoptosis Dopaminergic neurons LUHMES Neurodegeneration Parkinson's disease

Journal

Neurochemistry international
ISSN: 1872-9754
Titre abrégé: Neurochem Int
Pays: England
ID NLM: 8006959

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 22 06 2023
revised: 01 09 2023
accepted: 03 09 2023
medline: 23 10 2023
pubmed: 8 9 2023
entrez: 7 9 2023
Statut: ppublish

Résumé

The debilitating effects of Parkinson's disease (PD) progress over time and are pathophysiologically characterized by the formation of Lewy bodies due to the accumulation of α-synuclein aggregates resulting in the death of dopaminergic neurons. In the present study, we determined cell death pathways activated by acute exposure to 6-hydroxydopamine (6-OHDA) in differentiated LUHMES cells empirically followed by a 24 h toxin free interval, henceforth termed as washout/recovery period. Acute 6-OHDA exposure led to morphological changes in LUHMES cells and resulted in significant loss of neurite length and neurite thickness. Generation of reactive oxygen species and loss of mitochondrial membrane potential in the neuronal processes were persistent even after the recovery period. Our results show that 6-OHDA exposure leads to significant reduction in expression of mitochondrial OXPHOS complexes I, II, and IV and activation of caspase mediated apoptotic cell death cascade as observed by enhanced protein expression of cleaved-PARP-1 and cleaved-Caspase-3. Immunofluorescence microscopy approach confirmed that cell death occurs independent of the AIF translocation to the nucleus. Our experimental model, led to a ∼5-fold lower α-synuclein monomer expression and, interestingly, resulted in loss of protein ubiquitination in whole cell lysates. Altogether, this work provides evidence of multiple pathways targeted by 6-OHDA in differentiated LUHMES cells and expands research avenues for addressing the knowledge gap regarding the effect of 6-OHDA in the ubiquitin proteasome system for PD therapies.

Identifiants

pubmed: 37678429
pii: S0197-0186(23)00136-5
doi: 10.1016/j.neuint.2023.105608
pii:
doi:

Substances chimiques

Oxidopamine 8HW4YBZ748
alpha-Synuclein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105608

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Nilufar Ali (N)

Department of Research and Development, Azymus Therapeutics Inc., Boise, ID, USA; Department of Biological Science, Boise State University, Boise, ID, USA. Electronic address: nilufarali@boisestate.edu.

Mukta S Sane (MS)

Department of Research and Development, Azymus Therapeutics Inc., Boise, ID, USA.

Huiyuan Tang (H)

Department of Research and Development, Azymus Therapeutics Inc., Boise, ID, USA.

Jadon Compher (J)

Department of Research and Development, Azymus Therapeutics Inc., Boise, ID, USA.

Quinlan McLaughlin (Q)

Department of Research and Development, Azymus Therapeutics Inc., Boise, ID, USA.

Christopher D Jones (CD)

Department of Regulatory and Medical Affairs, Azymus Therapeutics Inc., Boise, ID, USA. Electronic address: Chris@jonesfamilies.org.

Shivani Kaushal Maffi (SK)

Department of Research and Development, Azymus Therapeutics Inc., Boise, ID, USA. Electronic address: maffishivani@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH